不同剂量布地奈德雾化吸入治疗小儿哮喘急性发作的临床效果

目的比较不同剂量布地奈德雾化吸入治疗小儿哮喘急性发作的效果。方法选取我院2016年9月至2018年5月收治的120例哮喘急性发作期患儿为研究对象,采用随机数表法将其分为A、B、C、D组,各30例。四组均进行抗感染、氧疗等基础对症治疗,D组在此基础上结合注射甲基泼尼松龙;A、B、C三组在此基础上均采用布地奈德联合硫酸沙丁醇雾化吸入进行治疗,三组布地奈德的使用剂量分别为0.5、1.0、1.5 mg。比较四组患儿临床症状评分、肺功能指标及不良反应发生情况。结果治疗后,四组患儿咳嗽积分、喘息积分、肺音积分及总积分均显著降低,且A、B、C三组低于D组,B组C组> A组,差异有统计学意义(P <0. 05)。A、B、C三组不良反应总发生率均明显低于D组,且A、B两组明显低于C组,差异具有统计学意义(P<0.05)。结论应用1.0 mg布地奈德联合硫酸沙丁胺醇雾化吸入治疗小儿哮喘急性发作效果显著,且用药安全性高,值得临床应用。

Effects of different doses of budesonide aerosol inhalation in the treatment of acute attack of infantil asthma

Objective To compare the effects of different doses of budesonide aerosol inhalation in the treatment of acute attack of infantil asthma. Methods A total of 120 children with acute attack of asthma in our hospital from September 2016 to May 2018 were selected as the research objects. They were divided into group A, B, C and D by random number table method, with 30 cases in each group. The four groups were treated with basic symptomatic treatment, such as anti-infection and oxygen therapy, the group D combined with methylprednisolone injection on this basis, the group A, B and C were treated with budesonide combined with salbutamol sulfate aerosol inhalation, and the doses of budesonide in the three groups were 0.5, 1.0 and 1.5 mg respectively. The scores of clinical symptoms, pulmonary function indexes and occurrence of adverse reactions were compared among the four groups. Results After treatment, the scores of cough, asthma and lung rale and total scores of the four groups significant decreased, and those in the group A, B and C were significantly lower than the group D, those decreased in turns in the group B, group C and group A, the differences were statistically significant(P<0.05);FEV1/FVC and PEFR in the group A, B and C were significantly higher than those in group D, those increased in turns in the group B, group C and group A, and the differences were statistically significant(P<0.05). The total incidence of adverse reactions in the group A, B and C was significantly lower than the group D, and the incidence of adverse reactions in the group A and B was significantly lower than that in group C, and the differences were statistically significant(P<0.05). Conclusion The application of 1.0 mg budesonide combined with salbutamol sulfate aerosol inhalation in the treatment of acute attack of infantil asthma has a significant effect and high safety, which is worthy of clinical application.